Envestnet Portfolio Solutions Inc. Has $688,000 Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Envestnet Portfolio Solutions Inc. grew its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,094 shares of the medical research company’s stock after buying an additional 388 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Bio-Rad Laboratories were worth $688,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in BIO. Venturi Wealth Management LLC increased its position in Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the period. Picton Mahoney Asset Management lifted its holdings in Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after buying an additional 35 shares during the period. Asset Planning Inc bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at $33,000. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after acquiring an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. bought a new position in shares of Bio-Rad Laboratories in the 4th quarter worth about $38,000. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Up 0.3 %

BIO opened at $257.38 on Tuesday. The firm has a market capitalization of $7.21 billion, a PE ratio of -3.96 and a beta of 0.98. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories, Inc. has a fifty-two week low of $244.00 and a fifty-two week high of $387.99. The company’s 50-day moving average is $301.32 and its 200 day moving average is $324.70.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on BIO shares. Wells Fargo & Company cut their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.